随机化前eTICI评分与90天结局:ANGEL-TNK试验事后分析
该研究为ANGEL-TNK试验预设二次分析,纳入253例前循环大血管闭塞且血管内治疗再灌注达eTICI 2b50-3的患者,随机接受动脉内替奈普酶(TNK)0.125 mg/kg或标准药物治疗。结果发现,eTICI 2b50-67患者接受动脉内TNK后90天mRS 0-1比例更高,而eTICI 2c-3患者无获益且任何颅内出血风险增加,症状性颅内出血和死亡风险未见差异。
要点
- eTICI 2b50-67患者动脉内TNK可提高90天mRS 0-1比例,但eTICI 2c-3患者无获益。
- eTICI 2c-3患者动脉内TNK增加48小时内任何颅内出血风险,但不增加症状性颅内出血或90天死亡。
核心结论
- 血管内治疗成功后动脉内TNK可为eTICI 2b50-67患者带来90天mRS 0-1的额外获益,但eTICI 2c-3患者无此获益且任何颅内出血风险增加。
研究设计与样本
- ANGEL-TNK试验的预设二次分析,多中心、随机、开放标签、盲法终点设计,共纳入253例前循环大血管闭塞患者。
主要发现
- eTICI 2b50-67组中动脉内TNK组90天mRS 0-1率为44.8%(39例) vs 19.5%(15例),RR 2.08(95%CI 1.35-3.21),P=0.001。
- eTICI 2c-3组中动脉内TNK组90天mRS 0-1率为30.8%(12例) vs 38.0%(19例),RR 0.84(95%CI 0.29-2.44),P=0.749。
- eTICI 2c-3组中动脉内TNK组48小时内任何颅内出血率为33.3%(13例) vs 20.0%(10例),RR 1.70(95%CI 1.05-2.77),P=0.032。
- eTICI 2b50-67组中48小时内任何颅内出血率为20.7%(18例) vs 32.5%(25例),RR 0.65(95%CI 0.34-1.22),P=0.176。
- 两组症状性颅内出血和90天死亡风险均未见显著差异。
关键数值与推荐
- 动脉内替奈普酶(TNK)剂量为0.125 mg/kg。
- 随机化分组比例为1:1,再灌注状态为eTICI 2b50至3。
- 主要结局为90天改良Rankin量表评分0-1的比例。
临床怎么用
- 对于血管内治疗再灌注达eTICI 2b50-67的前循环大血管闭塞患者,可考虑动脉内TNK以改善90天优良结局。
- 对于再灌注达eTICI 2c-3的患者,动脉内TNK不改善结局且增加任何颅内出血风险,应谨慎权衡。
局限性
- 本研究为事后分析,结果需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. BACKGROUND:Successful thrombectomy recanalization combined with intraarterial thrombolysis showed potential benefits in achieving excellent outcomes in recent trials, but the results were inconsistent. We performed this study to investigate the efficacy and safety of interarterial thrombolysis in patients stratified by expanded Thrombolysis in Cerebral Infarction (eTICI) score after thrombectomy.METHODS:This is a prespecified secondary analysis of the ANGEL-TNK trial (Intraarterial Recombinant Human TNK-tPA Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization; multicenter, randomized, open-label, blinded end point). Participants who had anterior circulation large artery occlusion were enrolled and randomized (1:1) to interarterial tenecteplase (TNK; 0.125 mg/kg) or standard medical management after eTICI 2b50 to 3 reperfusion. The primary outcome was the rate of 90-day modified Rankin Scale score 0 to 1. Safety outcomes included symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours, and death within 90 days.RESULTS:Of the 253 patients enrolled, 164 were in the eTICI 2b50 to 67 group, and 89 were in the eTICI 2c to 3 group. Interarterial TNK after EVT was associated with a higher rate of modified Rankin Scale score 0 to 1 at 90 days in patients with an eTICI score of 2b50 to 67 (39 [44.8%] versus 15 [19.5%]; relative risk, 2.08 [95% CI, 1.35–3.21];P=0.001), but not in those with eTICI 2c to 3 (12 [30.8%] versus 19 [38.0%]; relative risk, 0.84 [95% CI, 0.29–2.44];P=0.749). In the eTICI 2c to 3 group, interarterial TNK resulted in more cases of any intracranial hemorrhage within 48 hours (13 [33.3%] versus 10 [20.0%]; relative risk, 1.70 [95% CI, 1.05–2.77];P=0.032), but not in the eTICI 2b50 to 67 group (18 [20.7%] versus 25 [32.5%]; relative risk, 0.65 [95% CI, 0.34–1.22];P=0.176). The difference was not observed in symptomatic intracranial hemorrhage within 48 hours or death within 90 days in either group.CONCLUSIONS:Interarterial TNK after EVT provides additional benefits for excellent outcomes, defined as a modified Rankin Scale score of 0 to 1 at 90 days, in patients with an eTICI score of 2b50 to 67, but not in those with eTICI 2c to 3. It increases the risk of any intracranial hemorrhage in patients with an eTICI score of 2c to 3, without elevating the risk of symptomatic intracranial hemorrhage or death.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifie
引用
- Stroke:Relationship Between the eTICI Score Before Randomization and 90-Day Outcome: A Post Hoc Analysis of ANGEL-TNK Trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。